Yield10 Bioscience Inc
NASDAQ:YTEN
Yield10 Bioscience Inc
NASDAQ:YTEN
Price:
0.2299 USD
6.44%
Market Closed
Updated:
May 2, 2024
P/E
Price to Earnings
Price to Earnings
-0.2
Current
-3.3
Median
26.2
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-0.2
Market Cap
/
3.5m
Net Income
-14.5m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Yield10 Bioscience Inc
NASDAQ:YTEN
|
3.5m USD | -0.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 58.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 22 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 28.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 25.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 35.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 167.6 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | -9.7 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 26.8 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 72.5 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-0.3
2-Years Forward
P/E
-0.3
3-Years Forward
P/E
-1.6
You don't have any saved screeners yet
